FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer - Dr. Jacob Sands

In this episode of the Oncology Brothers podcast, Drs. Rohit & Rahul Gosain welcome Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, to discuss the recent FDA approval of Dato-DXD (datopotamab deruxtecan) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC).

Key Topics:
•⁠ ⁠Overview of Dato-DXd and its FDA approval
•⁠ ⁠Mechanism of action and study design of the TROPION Lung trials
•⁠ ⁠Efficacy and safety profile of Dato-DXd
•⁠ ⁠Management of side effects and clinical pearls
•⁠ ⁠Treatment sequencing for EGFR-mutated NSCLC

Join us as we dive into the details of the TROPION Lung trials that led to this significant approval, the mechanism of action of Dato-DXd, and the implications for patients with various EGFR mutations.
Dr. Sands shared insights on the study design, efficacy, and tolerability of this new antibody-drug conjugate, as well as important clinical pearls for managing side effects such as stomatitis, dry eyes, and interstitial lung disease (ILD).
We also explored the current treatment landscape for EGFR-mutated NSCLC, including the sequencing of therapies and the potential role of Dato-DXd in clinical practice.
Tune in for an informative discussion that highlights the exciting advancements in oncology and the hope they bring to patients.

Follow us on social media:
•⁠ ⁠X/Twitter:   / oncbrothers  
•⁠ ⁠Instagram:   / oncbrothers  
•⁠ Website: https://oncbrothers.com/

Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!

#TROPION #Lung01 #Lung05 #docetaxel #DatoDXd #TROPIONtrial #EGFRNSCLC #ADConcology #OncologyBrothers